Trial watch: Dendritic cell (DC)-based immunotherapy for cancer.
Raquel S LaureanoJenny SprootenIsaure VanmeerbeerkDaniel M BorrasJannes GovaertsStefan NaulaertsZwi N BernemanBenoit BeuselinckKalijn F BolJannie BorstAn CoosemansAngeliki DatsiJitka FučíkováLisa KingetBart NeynsGerty SchreibeltEvelien SmitsRüdiger V SorgRadek SpisekKris ThielemansSandra TuyaertsSteven De VleeschouwerI Jolanda M de VriesYanling XiaoAbhishek Dinkarnath GargPublished in: Oncoimmunology (2022)
Dendritic cell (DC)-based vaccination for cancer treatment has seen considerable development over recent decades. However, this field is currently in a state of flux toward niche-applications, owing to recent paradigm-shifts in immuno-oncology mobilized by T cell-targeting immunotherapies. DC vaccines are typically generated using autologous (patient-derived) DCs exposed to tumor-associated or -specific antigens (TAAs or TSAs), in the presence of immunostimulatory molecules to induce DC maturation, followed by reinfusion into patients. Accordingly, DC vaccines can induce TAA/TSA-specific CD8 + /CD4 + T cell responses. Yet, DC vaccination still shows suboptimal anti-tumor efficacy in the clinic. Extensive efforts are ongoing to improve the immunogenicity and efficacy of DC vaccines, often by employing combinatorial chemo-immunotherapy regimens. In this Trial Watch, we summarize the recent preclinical and clinical developments in this field and discuss the ongoing trends and future perspectives of DC-based immunotherapy for oncological indications.
Keyphrases
- dendritic cells
- regulatory t cells
- immune response
- clinical trial
- primary care
- phase iii
- photodynamic therapy
- stem cells
- papillary thyroid
- cell therapy
- cancer therapy
- palliative care
- drug delivery
- young adults
- radical prostatectomy
- peripheral blood
- rectal cancer
- locally advanced
- lymph node metastasis
- platelet rich plasma
- patient reported